The most common cancers with the TP53 mutations characteristic for the glycidamide-induced mutations were ovarian (10%) and breast (10%) cancer followed by ~ 8% each colorectal and lung cancer (Fig. 2b). The gene discussed is TP53; the disease is lung cancer.